Table 10
Reasons invoked to contract out bioproduct related
activities, Canada, 2009
Archived Content
Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please "contact us" to request a format other than those available.
Degree of importance | ||||
---|---|---|---|---|
Low | Medium | High | Not applicable | |
percent | ||||
Access outside scientific expertise/knowledge | 5.7A | 5.3A | 83.9A | 5.1A |
Activity area outside core competence of firm |
10.5A | 20.7A | 52.2B | 16.6A |
Faster completion of the work | 21.4A | 28.2A | 37.4A | 13.0A |
Lower risks to the firm | 34.3B | 30.0A | 18.1A | 17.6A |
Increase physical capacity (infrastructure, equipment, etc.) |
24.0A | 23.3A | 34.5B | 18.2A |
Access external R and D expertise | 8.4A | 30.7A | 45.0B | 15.9A |
Access regulatory affairs expertise | 33.3A | 26.8A | 23.0A | 16.9A |
Access production facilities | 48.2B | 8.1A | 16.6A | 27.1A |
Other | 0.0 | 1.1A | 2.4A | 96.5A |
Note(s):
Due to rounding, components may not add to totals
Source(s):
Statistics Canada, Bioproducts production and development survey 2009.
- Date modified: